Results 61 to 70 of about 31,380 (219)

Mutagenicity of hydroxyurea in lymphocytes from patients with sickle cell disease

Genetics and Molecular Biology, 2004
Hydroxyurea is commonly used in the treatment of myeloproliferative diseases and in patients with sickle cell disease (SCD). The use of this antineoplastic agent in patients with SCD is justified because of the drug's ability to increase fetal hemoglobin
Khayat André Salim, Guimarães Adriana Costa, Cardoso Plínio Cerqueira, Lima Patrícia Danielle Lima de, Bahia Marcelo de Oliveira, Antunes Lusânia M. Greggi, Burbano Rommel Rodríguez   +6 more
doaj  

Successful Topical Treatment of Hydroxyurea-Induced Ulcers Without Drug Discontinuation: A Case Report

Case Reports in Hematology
Hydroxyurea, an antineoplastic agent, is widely used to treat essential thrombocythemia and polycythemia vera. Although hydroxyurea-induced skin ulcers are uncommon, they are a recognized long-term adverse effect.
Yiming Wang, MinMin He, BoCheng Han, Qiwen Zhang, Rui Ma   +4 more
doaj   +1 more source

Hydroxyurea therapy for neurological and cognitive protection in pediatric sickle cell anemia in Uganda (BRAIN SAFE II): Protocol for a single-arm open label trial

Contemporary Clinical Trials Communications
Background: Children with sickle cell anemia (SCA) in Sub-Saharan Africa are at high risk of sickle cerebrovascular injury (SCVI). Hydroxyurea, a commonly used disease-modifying therapy, may reduce SCVI resulting in potential impact on reducing stroke ...
Vincent Mboizi, Catherine Nabaggala, Deogratias Munube, John M. Ssenkusu, Phillip Kasirye, Samson Kamya, Michael G. Kawooya, Amelia Boehme, Frank Minja, Ezekiel Mupere, Robert Opoka, Caterina Rosano, Richard Idro, Nancy S. Green   +13 more
doaj   +1 more source

Survival and mortality among users and non-users of hydroxyurea with sickle cell disease

Revista Latino-Americana de Enfermagem, 2015
OBJECTIVE: to estimate survival, mortality and cause of death among users or not of hydroxyurea with sickle cell disease.METHOD: cohort study with retrospective data collection, from 1980 to 2010 of patients receiving inpatient treatment in two Brazilian
Olinda Maria Rodrigues de Araujo, Maria Lúcia Ivo, Marcos Antonio Ferreira Júnior, Elenir Rose Jardim Cury Pontes, Ieda Maria Gonçalves Pacce Bispo, Eveny Cristine Luna de Oliveira   +5 more
doaj   +1 more source

A Multicenter, Open‐Label, Phase 2 Trial Comparing Crizanlizumab Combined With Standard Therapy to Standard Therapy Alone on Renal Function in Patients With Sickle Cell Nephropathy (STEADFAST)

American Journal of Hematology, EarlyView.
Kenneth I. Ataga, Pablo Bartolucci, Santosh L. Saraf, Vimal K. Derebail, Adlette Inati, Jeffrey D. Lebensburger, Laurie DeBonnett, Rodolfo D. Cancado, Claire C. Sharpe   +8 more
wiley   +1 more source

Diagnosis and Management of Prenatal Hereditary Pyropoikilocytosis

Prenatal Diagnosis, EarlyView.
ABSTRACT Hereditary pyropoikilocytosis (HPP) is a severe hemolytic anemia caused by variants in SPTA1, SPTB, and EPB41. These weaken horizontal interactions in the erythrocyte cytoskeleton, causing membrane fragmentation and splenic sequestration. It will readily cause fetal anemia and often hydrops fetalis. Prenatal diagnosis requires first ruling out
Connor Hartzell, Samantha Stover, Nora Gibson, Timothy Olson, James Connelly, Matthew Grace, Jennifer Andrews   +6 more
wiley   +1 more source

In Utero HSC Transplantation for Sickle Cell Disease: A Potential Therapeutic Approach That Overcomes Complications of Current Therapies

Prenatal Diagnosis, EarlyView.
ABSTRACT Sickle cell disease (SCD) affects millions worldwide but has limited treatment options, most of which carry significant side effects. At present, the only curative treatment for SCD is allogeneic or gene‐modified autologous hematopoietic stem cell (HSC) transplantation (Tx).
Oluwaseun O. Babatunde, Madeleine G. Bibby, Anthony Atala, Graça Almeida‐Porada, Christopher D. Porada   +4 more
wiley   +1 more source

Sickle Cell Disease: Historical Overview and Current Therapies

Prenatal Diagnosis, EarlyView.
ABSTRACT Sickle cell disease (SCD) affects millions worldwide, yet the limited treatment options currently available do not always adequately control the disease and carry significant side effects. At present, the only curative treatment is hematopoietic stem cell (HSC) transplantation, a procedure that carries considerable challenges and numerous ...
Oluwaseun O. Babatunde, Madeleine G. Bibby, Anthony Atala, Graça Almeida‐Porada, Christopher D. Porada   +4 more
wiley   +1 more source

Identification of Yeast Protein Sequences With Similarity to the ESCRT‐III Protein Snf7

Yeast, EarlyView.
ABSTRACT Endosomal sorting complex required for transport (ESCRT‐III) is a membrane remodeling complex involved in a large number of cellular processes. It appears to perform an essential function in eukaryotes, since to date no eukaryotic organism completely devoid of ESCRT‐III has been found.
Thomas Brune, Ralf Kölling
wiley   +1 more source

Hydroxyurea-Increased Fetal Hemoglobin Is Associated with Less Organ Damage and Longer Survival in Adults with Sickle Cell Anemia.

PLoS ONE, 2015
BackgroundAdults with sickle cell anemia (HbSS) are inconsistently treated with hydroxyurea.ObjectivesWe retrospectively evaluated the effects of elevating fetal hemoglobin with hydroxyurea on organ damage and survival in patients enrolled in our ...
Courtney D Fitzhugh, Matthew M Hsieh, Darlene Allen, Wynona A Coles, Cassie Seamon, Michael Ring, Xiongce Zhao, Caterina P Minniti, Griffin P Rodgers, Alan N Schechter, John F Tisdale, James G Taylor   +11 more
doaj   +1 more source